Adaptimmune Therapeutics Management
Management criteria checks 3/4
Adaptimmune Therapeutics' CEO is Ad Rawcliffe, appointed in Sep 2019, has a tenure of 4.58 years. total yearly compensation is $2.77M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $303.02K. The average tenure of the management team and the board of directors is 4.3 years and 9.1 years respectively.
Key information
Ad Rawcliffe
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 23.4% |
| CEO tenure | 4.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 9.1yrs |
Recent management updates
Recent updates
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth
Apr 15Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%
Mar 15Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?
Feb 17
Have Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Been Selling Their Stock?
Jan 22Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
Jan 15Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Enjoyed An Impressive 227% Share Price Gain
Dec 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$650k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$650k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$175m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$4m | US$617k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$140m |
| Dec 31 2020 | US$3m | US$574k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$123m |
| Jun 30 2020 | n/a | n/a | -US$127m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$2m | US$500k | -US$137m |
| Sep 30 2019 | n/a | n/a | -US$144m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$102m |
| Dec 31 2018 | US$1m | US$457k | -US$96m |
| Sep 30 2018 | n/a | n/a | -US$87m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$69m |
| Dec 31 2017 | US$2m | US$444k | -US$70m |
Compensation vs Market: Ad's total compensation ($USD2.77M) is above average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.
CEO
Ad Rawcliffe (51 yo)
4.6yrs
Tenure
US$2,774,041
Compensation
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 4.6yrs | US$2.77m | 0.10% $ 303.0k | |
| Co-Founder & Chief Business & Strategy Officer | no data | US$1.18m | 0.12% $ 342.1k | |
| Chief Financial Officer | 4yrs | US$1.17m | 0.0063% $ 18.2k | |
| Chief Operating Officer | 7.1yrs | US$1.22m | 0.064% $ 187.1k | |
| Chief Medical Officer | 4.3yrs | US$1.18m | 0.037% $ 107.9k | |
| Chief Scientific Officer | 1.9yrs | no data | 0.0049% $ 14.2k | |
| VP of Corporate Affairs & Investor Relations | no data | no data | no data | |
| Senior VP & General Council | 8.5yrs | no data | no data | |
| Senior Director of Corporate Communications | no data | no data | no data | |
| Chief Patient Supply Officer | 4.7yrs | US$1.72m | 0.053% $ 155.2k | |
| Senior Vice President of Late Stage Development | 4.3yrs | no data | no data | |
| Chief Commercial Officer | less than a year | US$2.19m | 0.021% $ 62.0k |
4.3yrs
Average Tenure
53yo
Average Age
Experienced Management: ADAP's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 4.6yrs | US$2.77m | 0.10% $ 303.0k | |
| Independent Chairman of the Board of Directors | 9.2yrs | US$174.83k | 0% $ 0 | |
| Independent Non-Executive Director | 9.2yrs | US$111.54k | 0% $ 0 | |
| Independent Non-Executive Director | 9.1yrs | US$128.80k | 0.0094% $ 27.2k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 5.8yrs | US$117.25k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data |
9.1yrs
Average Tenure
58.5yo
Average Age
Experienced Board: ADAP's board of directors are considered experienced (9.1 years average tenure).